Is Vera Therapeutics, Inc. (VERA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.8% / 30% | 25.6% / 30% | 0.1% / 30% | N/A | ✓ HALAL |
| DJIM | 2.8% / 33% | 25.6% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| MSCI | 10.5% / 33% | 97.3% / 33% | 0.4% / 33% | N/A | ✗ NOT HALAL |
| S&P | 2.8% / 33% | 25.6% / 33% | 0.1% / 33% | N/A | ✓ HALAL |
| FTSE | 10.5% / 33% | 97.3% / 33% | 0.4% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -50.7% | |
| Return on Assets (ROA) | -28.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$241M |
| Free Cash Flow | -$242M |
| Total Debt | $77M |
| Debt-to-Equity | 12.8 |
| Current Ratio | 13.6 |
| Total Assets | $735M |
Price & Trading
| Last Close | $40.26 |
| 50-Day MA | $42.37 |
| 200-Day MA | $32.96 |
| Avg Volume | 1.1M |
| Beta | 1.2 |
|
52-Week Range
$18.53
| |
About Vera Therapeutics, Inc. (VERA)
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Vera Therapeutics, Inc. (VERA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Vera Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Vera Therapeutics, Inc.'s debt ratio?
Vera Therapeutics, Inc.'s debt ratio is 2.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 10.5%.
What are Vera Therapeutics, Inc.'s key financial metrics?
Vera Therapeutics, Inc. has a market capitalization of $2.8B. Return on equity stands at -50.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.